Add Angelman Syndrome

[caufieldjh]

No description provided.

[claude]

Claude finished @caufieldjh's task in 5m 15s —— View job

---

PR Review: Add Angelman Syndrome

Tasks:

• Gather context and read changed files
• Review biological and clinical validity
• Review conformance with guidelines
• Review completeness
• Verify key evidence snippets against reference cache
• Post final review

---

Overall Assessment

This is a high-quality, comprehensive entry for Angelman Syndrome. The biological and clinical content is accurate, the pathophysiology chain is coherent, and the evidence is well-sourced. A few issues are worth addressing before merge.

---

Biological and Clinical Validity ✅

The entry accurately captures AS pathophysiology:

• Molecular cascade is correctly modeled: maternal UBE3A disruption → neuron-specific paternal imprinting → reduced UBE3A protein → decreased ubiquitination → dysregulated signaling → synaptic remodeling defects → E/I imbalance → cortical hyperexcitability → seizures + cognitive impairment
• Molecular subtypes are correctly proportioned (deletion ~70%, UBE3A variant 6–11%, UPD 3%, imprinting defect 1%)
• Cardinal clinical features are accurately represented (severe ID, absent speech, ataxia, seizures, characteristic happy demeanor, microcephaly)
• Contemporary therapeutics are reflected, including ASO-based UBE3A reinstatement strategies (NCT04428281, NCT04259281)
• Multiple verified evidence snippets match source abstracts (PMID:14510623, PMID:24876791, PMID:40671377, PMID:40310720, etc.)

The evidence_source: OTHER classification for PMID:33543479 (Elgersma & Sonzogni 2021 review) is appropriate per CLAUDE.md guidelines. Mouse model citations are correctly labeled MODEL_ORGANISM. The iPSC-derived neuron studies (PMID:40671377) are correctly labeled IN_VITRO.

---

Issues to Address

🔴 Medium Priority

1. Missing clinical trial status fields

All three clinical trials omit the status field, which is listed in the schema's example structure. More critically, NCT04106557 (OV101/gaboxadol) was terminated due to futility — omitting this status could mislead readers about available treatments.

# kb/disorders/Angelman_Syndrome.yaml, line 1062
- name: NCT04106557
  phase: PHASE_III
  # status: Terminated  ← missing

Suggest adding status to all three trials:

• NCT04428281 → Recruiting or current status
• NCT04259281 → was placed on clinical hold; verify current status
• NCT04106557 → Terminated

Fix this →

2. Scoliosis frequency inconsistency

The cited evidence for scoliosis states it is "observed in >80% of patients" (PMID:14510623, the same snippet that supports seizures and microcephaly). Yet scoliosis is classified as FREQUENT while seizures and microcephaly are VERY_FREQUENT. This is internally inconsistent with the cited evidence.

# kb/disorders/Angelman_Syndrome.yaml, line 709–722
- name: Scoliosis
  category: Musculoskeletal
  frequency: FREQUENT   # ← evidence says >80%; should be VERY_FREQUENT OR use a more nuanced citation

Resolution options:

• Upgrade to VERY_FREQUENT if the >80% estimate from Guerrini 2003 is still accepted
• Or cite a more contemporary source with a lower prevalence estimate to justify FREQUENT

Fix this →

---

🟡 Low Priority

3. Orphaned GEO reference cache files

Three GEO cache files were added to references_cache/ but are not referenced in the disorder YAML. The most notable is GSE160747, which is directly AS-relevant:

Cache file	Description	Disposition
GEO_GSE160747.md	"Establishing a molecular phenotype for AS stem cell-derived neurons" — mRNAseq on isogenic control vs AS iPSC-derived neurons + ASO treatment	Recommend adding as dataset — directly relevant to UBE3A reinstatement mechanisms
GEO_GSE12231.md	Mouse imprinting study of proximal Chr 7/15 duplication (PWS/AS locus)	Optional — primarily a mouse imprinting model
GEO_GSE43900.md	Topoisomerase inhibitors and autism candidate genes	Likely incidental — only tangentially related

If GSE160747 was intentionally omitted, please clarify. Otherwise, it should be included or the cache file removed.

4. HERC2 differential diagnosis lacks MONDO term

The Prader-Willi syndrome and Houge-Janssens syndrome differentials both include disease_term blocks with MONDO IDs. The HERC2 differential does not:

# kb/disorders/Angelman_Syndrome.yaml, line 912
- name: HERC2-related Angelman-like neurodevelopmental disorder
  description: ...
  # disease_term: missing ← consider adding MONDO:0033867 or equivalent

MONDO:0033867 (HERC2-related intellectual disability syndrome) or a similar term could be added for consistency.

5. PMID:40877933 not in reference cache

The dataset geo:GSE284678 cites this PMID in its publication: metadata field, but references_cache/PMID_40877933.md does not exist. This is a minor metadata gap (not in an evidence block), but worth noting for completeness.

---

Strengths Worth Calling Out

• Excellent pathophysiology depth: The multi-step cascade from UBE3A loss → ubiquitination defects → synaptic remodeling → E/I imbalance → clinical phenotypes is well-structured with supporting evidence at each step
• Balanced evidence source classification: Correct use of HUMAN_CLINICAL, MODEL_ORGANISM, IN_VITRO, and OTHER throughout
• Strong genomic dataset coverage: 4 GEO datasets spanning human iPSC-derived neurons, mouse models, and human peripheral blood
• Therapeutically current: Includes cutting-edge ASO-based UBE3A reinstatement trials
• Good differential coverage: Includes Prader-Willi syndrome (key molecular differential), HERC2-related disorder, and the recently described Houge-Janssens syndrome

---

Summary

The entry is scientifically sound and ready for merge with minor fixes. The most important issue is adding status fields to the three clinical trials — particularly noting that NCT04106557 (OV101/gaboxadol) was terminated. The scoliosis frequency inconsistency and orphaned GEO cache files are secondary concerns.

[claude]

Claude finished @caufieldjh's task in 3m 2s —— View job

---

PR Review Update: Add Angelman Syndrome

Tasks:

• Gather context and read changed files
• Check what changed since the last review
• Verify previous issues were addressed
• Post updated review

---

Review of "Address review comments" Commit

The author has addressed most of the issues raised in the previous review. Here's the status of each:

Issue	Status
Scoliosis frequency: FREQUENT → VERY_FREQUENT	✅ Fixed
HERC2 differential — add MONDO term	✅ Fixed (MONDO:0014224 added)
Add GEO GSE160747 as dataset	✅ Fixed (added with full evidence block)
PMID:40877933 reference cache	✅ Fixed (file added)
Clinical trial status fields — NCT04428281, NCT04259281	✅ Fixed (both set to COMPLETED)
NCT04106557 (OV101/gaboxadol) — should be TERMINATED	❌ Still wrong — set to COMPLETED
GEO_GSE12231 / GEO_GSE43900 orphaned cache files	⬜ Not addressed (minor, acceptable)

---

Remaining Issue: NCT04106557 Must Be TERMINATED

The OV101 (gaboxadol) Phase 3 STARS trial (NCT04106557) did not complete — it was terminated due to insufficient efficacy. Ovid Therapeutics/Takeda discontinued OV101 after the trial failed to meet primary or secondary endpoints. Setting this to COMPLETED is factually incorrect and could mislead readers into thinking gaboxadol is an established AS therapy.

The schema has an explicit TERMINATED status for exactly this case:

TERMINATED: Stopped before completion, may include safety or efficacy concerns

Fix needed in kb/disorders/Angelman_Syndrome.yaml:

- name: NCT04106557
  phase: PHASE_III
  status: TERMINATED   # ← was incorrectly set to COMPLETED
  description: >-
    Randomized placebo-controlled phase III study of oral OV101 (gaboxadol) in
    pediatric Angelman syndrome. Trial terminated due to insufficient efficacy;
    OV101 did not meet primary or secondary endpoints.

I applied this fix locally but was unable to push due to repository permissions. Please apply this change to the branch.

Fix this →

---

Minor Notes (non-blocking)

• GEO_GSE12231 / GEO_GSE43900: These cache files remain orphaned (not referenced in the YAML). As noted in the initial review, GSE43900 is only tangentially related and GSE12231 is a mouse imprinting model — acceptable to leave as-is or remove.
• MONDO:0014224 label: The term label developmental delay with autism spectrum disorder and gait instability is used for the HERC2 differential. This differs from the preferred_term (HERC2-related Angelman-like neurodevelopmental disorder), which is correctly handled per the preferred_term vs term.label convention. Worth verifying with OAK (uv run runoak -i sqlite:obo:mondo info MONDO:0014224) before merge to confirm the label is canonical.

---

Summary

This is a high-quality entry that is close to merge-ready. The single blocking issue is the NCT04106557 status, which must be corrected to TERMINATED to accurately reflect that the gaboxadol trial was discontinued. All other previously raised issues have been addressed.